Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2017–2021

BBDiag · Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2017-01-01 → 2021-12-31
EU contribution
€3,434,981
Participants
14
Scheme
MSCA-ITN

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

The aim of the BBDiag project was to train a new generation of ESRs for early AD diagnosis based on blood biomarkers. Despite of the notable recent advances in AD biomarkers and diagnostics, dementia is still one of the Societal Challenges listed by the UN and EU. BBDiag responded to such a need and established this ETN for blood based early-AD diagnostics. BBDiag Fellows were trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary skills as well as personal quality, creative thinking and business mind-set. The ETN had a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag delivered its first generation of highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

Data: CORDIS, © European Union

Project objective

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in clinical drug intervention trials is among the main reasons for many notable trial failures. The main challenges in developing the required diagnostics are identification of AD biomarkers and development of their detection techniques. The complex and interdisciplinary nature of the research underlines the need for innovative training of a new generation of researchers in the field. BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial experts from five major consortia in Europe and uses their synergies to build a triple-i research & training platform with the required multidisciplinary expertise and cutting-edge technologies. BBDiag Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary scientific and transferable skills as well as personal quality, creative thinking and business mind-set. The ETN has a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag will deliver its first generation of 13 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

Original text from CORDIS.

Participants

  • UNIVERSITY OF PLYMOUTH · PlymouthCoordinatorUnited Kingdom
  • ADVANCED MEDICAL PROJECTS SOCIEDAD LIMITADA · GuadalajaraCity levelSpain
  • CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS · SevillaSpain
  • China Capital Medical University · BeijingChina
  • DANMARKS TEKNISKE UNIVERSITET · Kongens LyngbyDenmark
  • ENGAGE - KEY TECHNOLOGY VENTURES AG · KarlsruheGermany
  • HUNAN UNIVERSITY · CHANGSHAChina
  • ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI · MILANOItaly
  • NORDIC BIOSCIENCE A/S · HerlevDenmark
  • PROGNOMICS LTD · SWANSEAUnited Kingdom
  • Re:Cognition Health Ltd. · LondonUnited Kingdom
  • SWANSEA UNIVERSITY · SwanseaUnited Kingdom
  • UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA · RomaItaly
  • UNIVERSITATSMEDIZIN ROSTOCK · RostockGermany

Links

Data: CORDIS, © European Union